Effect of alpha-glucosidase inhibitors on the progression of carotid intima-media thickness: A meta-analysis of randomized controlled trials

Atherosclerosis

Volumn 218, Issue 1, 2011, Pages 214-219

  Geng, Deng feng ^a   Jin, Dong mei ^a   Wu, Wei ^a   Fang, Chang ^a   Wang, Jing feng ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Alpha glucosidase inhibitors; Carotid intima media thickness; Diabetes, type 2; Impaired glucose tolerance

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ABDOMINAL DISCOMFORT; ANGINA PECTORIS; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROGENESIS; CLINICAL TRIAL; DIABETIC PATIENT; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DRUG EFFICACY; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; IMPAIRED GLUCOSE TOLERANCE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

AGED; ALPHA-GLUCOSIDASES; ATHEROSCLEROSIS; BLOOD PRESSURE; CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80052274088     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.05.004     Document Type: Article

References (27)

1. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27(5):1047-1053.
2. Cowie C.C., Rust K.F., Ford E.S., et al. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006. Diabetes Care 2009, 32:287-294.
3. Bonora E., Muggeo M. Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 2001, 44(12):2107-2114.
4. Hanefeld M., Fischer S., Julius U., et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996, 39(12):1577-1583.
5. Tominaga M., Eguchi H., Manaka H., et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata diabetes study. Diabetes Care 1999, 22(6):920-924.
6. Hodis H.N., Mack W.J., LaBree L., et al. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128(4):262-269.
7. O'Leary D.H., Polak J.F., Kronmal R.A., et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999, 340:14-22.
8. Bots M.L., Hoes A.W., Koudstaal P.J., Hofman A., Grobbee D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation 1997, 96:1432-1437.
9. Lorenz M.W., Markus H.S., Bots M.L., Rosvall M., Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115(4):459-467.
10. Puls W., Keup U., Krause H.P., Thomas G., Hoffmeister F. Glucosidase inhibition: a new approach to the treatment of diabetes, obesity, and hyperlipoproteinaemia. Naturwissenschaften 1977, 64:536-537.
11. Hanefeld M., Koehler C., Schaper F., et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 1999, 144(1):229-235.
12. Bonora E., Kiechl S., Oberhollenzer F., et al. Impaired glucose tolerance, type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck study. Diabetologia 2000, 43(2):156-164.
13. Sidhu J.S., Kaposzta Z., Markus H.S., Kaski J.C. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004, 24(5):930-934.
14. Geng D.F., Jin D.M., Wu W., Wang Z., Wang J.F. Effect of thiazolidinediones on in-stent restenosis in patients after coronary stenting: a meta-analysis of randomized controlled trials. Atherosclerosis 2009, 202(2):521-528.
15. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions 4.2.5. 2005 update.
16. Hanefeld M., Chiasson J.L., Koehler C., et al. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004, 35(5):1073-1078.
17. Oyama T., Saiki A., Endoh K., et al. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. J Atheroscler Thromb 2008, 15(3):154-159.
18. Koyasu M., Ishii H., Watarai M., et al. Impact of acarbose on carotid intima-media thickness in patients with newly diagnosed impaired glucose tolerance or mild type 2 diabetes mellitus: a one-year, prospective, randomized, open-label, parallel-group study in Japanese adults with established coronary artery disease. Clin Ther 2010, 32(9):1610-1617.
19. Yamasaki Y., Katakami N., Hayaishi-Okano R., et al. Alpha-glucosidase inhibitor reduces the progression of carotid intima-media thickness. Diabetes Res Clin Pract 2005, 67(3):204-210.
20. Nakamura T., Matsuda T., Kawagoe Y., et al. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 2004, 53(10):1382-1386.
21. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290(4):486-494.
22. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25(1):10-16.
23. Van de Laar F., Lucassen P. No evidence for a reduction of myocardial infarctions by acarbose [letter]. Eur Heart J 2004, 25:1179.
24. Hanefeld M. Meta-analysis of long-term studies to assess the effect of acarbose on cardiovascular risk reduction-scientifically credible [letter]. Eur Heart J 2004, 25:1179-1180.
25. van de Laar F.A., Lucassen P.L., Akkermans R.P., et al. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005, 28(1):154-163.
26. Acarbose cardiovascular evaluation trial (ClinicalTrials.gov identifier: ), [accessed 6 Feb 2011]. http://clinicaltrials.gov/ct2/show/NCT00829660.
27. Assessment of an alpha-glucosidase inhibitor to block cardiac events in patients with myocardial infarction and IGT (ABC study) (ClinicalTrials.gov identifier: ), [accessed 6 Feb 2011]. http://clinicaltrials.gov/ct2/show/NCT00212017.